Liraglutide administration in type 2 diabetic patients who either received no previous treatment or were treated with an oral hypoglycemic agent showed greater efficacy than that in patients switching from insulin

AIMS/INTRODUCTION: Liraglutide, a glucagon‐like peptide‐1 receptor agonist, is expected to provide a new treatment option for diabetes. However, the suitable timing of liraglutide administration in type 2 diabetic patients has not yet been clarified. MATERIALS AND METHODS: We reviewed type 2 diabeti...

Descripción completa

Detalles Bibliográficos
Autores principales: Nambu, Takuo, Matsuda, Yuki, Matsuo, Koji, Kanai, Yugo, Yonemitsu, Shin, Muro, Seiji, Oki, Shogo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley-Blackwell 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019290/
https://www.ncbi.nlm.nih.gov/pubmed/24843633
http://dx.doi.org/10.1111/j.2040-1124.2012.00242.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019290/
https://www.ncbi.nlm.nih.gov/pubmed/24843633
http://dx.doi.org/10.1111/j.2040-1124.2012.00242.x

Ejemplares similares